Lung Cancer

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.

The BLA for Dato-DXd in locally advanced or metastatic EGFR-mutated NSCLC has been accepted and granted priority review by the FDA.

Sunvozertinib gets priority review in EGFR-mutated NSCLC, iparomlimab/tuvonralimab combination elicits responses in cervical cancer, and more.

Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.

BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.

The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.

Amivantamab plus lazertinib prolonged overall survival vs osimertinib as first-line therapy in locally advanced or metastatic, EGFR-mutant NSCLC.

Sandip P. Patel, MD, discusses the potential role of antibody-drug conjugates in early-stage non–small cell lung cancer.

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.

The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.

China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.

The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

As a female leader in a competitive oncology field, Solange Peters, MD, PhD, pushed through the barriers— climbed over them—and completely transformed lung cancer care with her collaborative spirit.

Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Panelists discuss how the resectability of stage III non-small cell lung cancer tumors remains controversial, particularly regarding the role of surgery in multi-station N2 disease and the optimal sequencing of multimodality therapy.

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.